title: Understanding the roles of the P2X7 receptor in solid tumour progression and therapeutic perspectives.
abstract: P2X7 is an intriguing ionotropic receptor for which the activation by extracellular ATP induces rapid inward cationic currents and intracellular signalling pathways associated with numerous physiological processes such as the induction of the inflammatory cascade, the survival and proliferation of cells. In contrast, long-term stimulation of P2X7 is generally associated with membrane permeabilisation and cell death. Recently, P2X7 has attracted great attention in the cancer field, and particularly in the neoplastic transformation and the progression of solid tumours. A growing number of studies were published; however they often appeared contradictory in their results and conclusions. As such, the involvement of P2X7 in the oncogenic process remains unclear so far. The present review aims to discuss the current knowledge and hypotheses on the involvement of the P2X7 receptor in the development and progression of solid tumours, and highlight the different aspects that require further clarification in order to decipher whether P2X7 could be considered as a cancer biomarker or as a target for pharmacological intervention. This article is part of a Special Issue entitled: Membrane channels and transporters in cancers.
authors.affiliation: Inserm UMR1069 Nutrition, Croissance et Cancer, Université François-Rabelais de Tours, 10 Boulevard Tonnellé, 37032 Tours, France; Département de Physiologie Animale, UFR Sciences et Techniques, Université François-Rabelais de Tours, Avenue Monge, 37200 Tours, France. Electronic address: sebastien.roger@univ-tours.fr.
authors.forename: Sébastien
authors.initials: S
authors.lastname: Roger
authors.affiliation: Inserm UMR1069 Nutrition, Croissance et Cancer, Université François-Rabelais de Tours, 10 Boulevard Tonnellé, 37032 Tours, France.
authors.forename: Bilel
authors.initials: B
authors.lastname: Jelassi
authors.affiliation: UMR CNRS 7355 Experimental and Molecular Immunology and Neurogenetics, Université d'Orléans, 3B rue de la Ferollerie, F-45071 Orléans, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Couillin
authors.affiliation: Inflammation and Experimental Surgery Research Unit, CIBERehd, Clinical University Hospital "Virgen de la Arrixaca", Murcia's BioHealth Research Institute IMIB-Arrixaca, Carretera Cartagena-Madrid s/n, 30120 Murcia, Spain.
authors.forename: Pablo
authors.initials: P
authors.lastname: Pelegrin
authors.affiliation: Inserm UMR1069 Nutrition, Croissance et Cancer, Université François-Rabelais de Tours, 10 Boulevard Tonnellé, 37032 Tours, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Besson
authors.affiliation: School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, United Kingdom.
authors.forename: Lin-Hua
authors.initials: LH
authors.lastname: Jiang
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D000494:Allosteric Regulation; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000627:therapeutic use*; D016923:Cell Death / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002471:Cell Transformation, Neoplastic / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D018450:Disease Progression; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D020641:Polymorphism, Single Nucleotide; D058920:Purinergic P2X Receptor Antagonists / Q000138:chemical synthesis / Q000627:therapeutic use*; D058486:Receptors, Purinergic P2X7 / Q000235:genetics* / Q000378:metabolism; D015398:Signal Transduction
chemical_list: D000970:Antineoplastic Agents; C546468:P2RX7 protein, human; D058920:Purinergic P2X Receptor Antagonists; D058486:Receptors, Purinergic P2X7; D000255:Adenosine Triphosphate
keywords: Biomarker; Cancer; Extracellular ATP; P2X7; Pharmacological target